MitoRx Therapeutics is a platform biotechnology company headquartered in Oxford, England, developing novel mitochondrial-targeted therapeutics for life sciences.
Subscribe to see MitoRx Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MitoRx Therapeutics is a life sciences company headquartered in United Kingdom. It has raised at least $7.3M across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round, Pre-Series A, raised $7.3M in December 2025. Xcout tracks 12 named people at MitoRx Therapeutics, including Alison Strutt (Chief Financial Officer).
As of 16 November 2026. Source: Xcout Intel.
6 more named people on record for MitoRx Therapeutics, with roles, board committees and tenure — see the full roster →
At least $7.3M raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Pre-Series A | $7.3M | 1 named | |
| — | Undisclosed | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 3 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of MitoRx Therapeutics's closest competitors — see the full list of competitors and alternatives →
Mitotherapeutix, LLC is a biotechnology company that develops small interfering RNA (siRNA) based therapeutics targeting difficult disease pathways. The company focuses on modulating mitochondrial metabolic activity by inhibiting a negative gene regulator to treat a wide array of diseases.
Cellvie AG is a biotechnology company based in Zurich, Switzerland, pioneering Therapeutic Mitochondria Transplantation to target cellular energy metabolism.
ScandiBio Therapeutics is a clinical-stage biotechnology company headquartered in Stockholm, Sweden, founded to develop pharmaceutical drugs targeting mitochondrial dysfunction.
Abliva is a company headquartered in Lund, Sweden, focused on delivering mitochondrial health. It leverages in-house R&D capabilities to create a portfolio of projects with various mechanisms of action.
Pretzel Therapeutics is a biotechnology company headquartered in Boston, Massachusetts, advancing a new class of medicines that target cellular energetics and mitochondrial function.
Paean Holdings, Inc. (operating as PAEAN Biotechnology) develops mitochondria-based therapeutics designed to treat rare diseases, inflammatory conditions, cancer, and central nervous system disorders. The company utilizes proprietary platforms including mitochondrial transplantation, modified mitochondria for targeted delivery, and mitochondria-augmented cell therapy to address critical medical needs and overcome cellular metabolic limitations.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about MitoRx Therapeutics? Suggest a correction · Work at MitoRx Therapeutics? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.